• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avinger Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Other Events

    12/11/24 5:23:55 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care
    Get the next $AVGR alert in real time by email
    avgr20241211_8k.htm
    false 0001506928 0001506928 2024-12-11 2024-12-11
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549
     

     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of
    The Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported):
     
    December 11, 2024
     

     
    Avinger, Inc.
    (Exact name of registrant as specified in its charter)
     
    Delaware
    001-36817
    20-8873453
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (IRS Employer Identification No.)
     
    400 Chesapeake Drive
    Redwood City, California 94063
    (Address of principal executive offices, including zip code)
     
    (650) 241-7900
    (Registrant’s telephone number, including area code)
     
    Not Applicable
    (Former name or former address, if changed since last report.)
     
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $0.001 per share
    AVGR
    The Nasdaq Capital Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 2.04. Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.
     
    On December 11, 2024, Avinger, Inc. (the “Company”) filed with the Securities Exchange Commission (“SEC”) a preliminary proxy statement in connection with its special meeting of stockholders scheduled for January 17, 2025 (the “Special Meeting”). The preliminary proxy statement contains a proposal to approve an assignment for the benefit of creditors followed by a voluntary dissolution and liquidation if the Company’s board of directors deems such actions to be in the best interests of the Company and its stockholders. Such proposal may be deemed to be an event of default under Section 11.01(i) of that certain term loan agreement dated September 22, 2015 (as amended, modified or supplemented from time to time) by and between the Company and CRG Partners III L.P. and certain of its affiliated funds (collectively “CRG”) (the “CRG Agreement”).
     
    Additionally, on December 11, 2024, the Company notified CRG, pursuant to Section 8.02 of the CRG Agreement, that it was not in compliance with the $3,500,000 minimum liquidity covenant required by Section 10.01 of the CRG Agreement. Failure to remain in compliance with such liquidity covenant is an immediate event of default under Section 11.01(d) of the CRG Agreement.
     
    Under the terms of the CRG Agreement, upon the occurrence of an event of default under Section 11.01(i), the principal, accrued interest, fees and other obligations become immediately due and payable without further action or notice from CRG.
     
    Under the terms of the CRG Agreement, upon the occurrence of an event of default under Section 11.01(d), the Majority Lenders (as defined in the CRG Agreement) may, at their discretion and upon notice to the Company, accelerate the outstanding balance under the CRG Agreement, making the principal, accrued interest, fees and other obligations, immediately due and payable.
     
    As of December 11, 2024, a total of approximately $2.8 million in principal and interest was outstanding under the CRG Agreement.
     
    Item 8.01. Other Matters.
     
    On December 11, 2024, the Company filed with the SEC a preliminary proxy statement in connection with the Special Meeting. The preliminary proxy statement contains a proposal (the “Assignment and Dissolution Proposal”) to approve an assignment for the benefit of creditors (the “Assignment”) followed by a voluntary dissolution and liquidation (the “Dissolution”) pursuant to a plan of dissolution.
     
    The Assignment is a state-governed insolvency procedure in which the Company would transfer all of its right, title, interest in, and custody and control of, its property to an assignee (the “Assignee”). The Assignee will then liquidate the property and distribute the proceeds to the Company’s creditors to satisfy its obligations. From the effective date of the Assignment, the Assignee, as a fiduciary, will have sole control over the Company’s assets and the Company will no longer control its operations, the liquidation or distribution of assets or the resolution of claims. Because the Company does not know the final amount which the Assignee will recover from a liquidation of the Company’s assets or how the Assignee will resolve the Company’s outstanding obligations, the Company does not know whether any amounts will be available for distribution to holders of its common stock; however, based upon the Company’s current outstanding liabilities it is unlikely that holders of its common stock will receive any distribution.
     
     

     
     
    The Company expects that, in connection with the proposed Assignment and Dissolution, if effected, the Company’s common stock would be delisted from Nasdaq.
     
    Additional Information
     
    The Company intends to file a definitive proxy statement on Schedule 14A, an accompanying proxy card and other relevant documents with the SEC in connection with the solicitation of proxies from the Company’s stockholders for the Special Meeting. STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE COMPANY’S DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders may obtain a copy of the definitive proxy statement, an accompanying proxy card, any amendments or supplements to the definitive proxy statement and other documents filed by the Company with the SEC at no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge in the “SEC Filings” section of the Company’s website at https://investors.avinger.com/financials, as soon as reasonably practicable after such materials are electronically filed with, or furnished to, the SEC.
     
    Participants in the Solicitation
     
    The Company, its directors, and certain of its executive officers are participants in the solicitation of proxies from the Company’s stockholders in connection with matters to be considered at the Special Meeting. Information regarding the direct and indirect interests, by security holdings or otherwise, of the Company’s directors and executive officers is included in the Company’s Proxy Statement on Schedule 14A for its 2024 annual meeting of stockholders, filed with the SEC on November 5. 2024, the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 20, 2024, and in the Company’s Current Reports on Form 8-K filed with the SEC from time to time. Changes to the direct or indirect interests of the Company’s directors and executive officers are set forth in SEC filings on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4. These documents are available free of charge as described above.
     
    Forward-Looking Statements
     
    This Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve substantial risks and uncertainties and are based on the Company’s current expectations, estimates, and projections about its business, financial condition, and other future events. Forward-looking statements include, but are not limited to, statements regarding: the company’s plans and intentions to pursue an assignment for the benefit of creditors and dissolution, including the anticipated timing, process, and outcome of such assignment and dissolution; the anticipated timing, process, and outcome of the process to obtain stockholder approval of the assignment and dissolution at the Special Meeting; the company’s discussions with its creditors and other stakeholders in connection with its financial condition and potential breach of its loan agreement; and any other statements regarding the company's future financial condition, operations, or prospects.
     
    These forward-looking statements are subject to numerous risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed or implied in these statements. Important factors that could cause actual results to differ materially include, but are not limited to: risks associated with the assignment for the benefit of creditors, including the risk that the process may not achieve the intended results or may result in lower-than-expected recoveries for creditors or stakeholders; the impact of the potential breach of the Company’s loan agreement on its financial position, including potential enforcement actions by lenders; the Company’s ability to obtain stockholder approval of the assignment and dissolution; and other risks detailed in the Company’s filings with the SEC including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
     
    The Company cautions investors not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this Form 8-K, except as required by law.
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
         
    AVINGER, INC.
             
             
     
    Date: December 11, 2024
    By:
    /s/ Jeffrey M. Soinski
     
         
    Jeffrey M. Soinski
    Chief Executive Officer
     
     
    Get the next $AVGR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVGR

    DatePrice TargetRatingAnalyst
    11/15/2021$2.50 → $2.00Buy
    Aegis Capital
    6/29/2021$2.50Buy
    B. Riley Securities
    More analyst ratings

    $AVGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avinger Reports Third Quarter 2024 Results

    Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024.Third Quarter and Recent HighlightsReported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.Implemented cost reduction program designed to streamline operating costs of the peripheral business and increase focus on coronary product development

    11/7/24 4:05:00 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Avinger to Announce Third Quarter 2024 Results on November 7, 2024

    REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1- 973-528-0011 and use passcode 442577. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.co

    10/29/24 8:00:00 AM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Avinger Releases Updated Data From IMAGE-BTK in Webinar Featuring Key Opinion Leaders in the Field of Vascular Intervention

    REDWOOD CITY, CA / ACCESSWIRE / October 24, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease hosted a physician-focused webinar entitled, "New Approaches to Treating Peripheral Artery Disease (PAD) Below-the-Knee (BTK) and Promising New BTK Data." A recording of the webinar may be accessed at https://pages.avinger.com/webinar-new-approaches-to-treating-btk-pad.The webinar featured key opinion leaders in the field of vascular intervention from different specialties and geographies as follows:Dr. Michael Lichtenberg, an angiologist and the

    10/24/24 8:00:00 AM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    $AVGR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Avinger Inc.

    SCHEDULE 13G/A - Avinger Inc (0001506928) (Subject)

    2/14/25 5:07:21 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Avinger Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Changes in Registrant's Certifying Accountant, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Avinger Inc (0001506928) (Filer)

    2/10/25 5:01:26 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Avinger Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Avinger Inc (0001506928) (Filer)

    2/5/25 5:00:31 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    $AVGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Vice President, Finance Subainati Nabeel Paul sold $699 worth of shares (1,255 units at $0.56), decreasing direct ownership by 28% to 3,296 units (SEC Form 4)

    4 - Avinger Inc (0001506928) (Issuer)

    1/24/25 9:35:20 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Soinski Jeffrey M sold $2,054 worth of shares (3,690 units at $0.56), decreasing direct ownership by 6% to 55,265 units (SEC Form 4)

    4 - Avinger Inc (0001506928) (Issuer)

    1/24/25 9:34:44 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Chief Technology Officer Patel Himanshu sold $1,233 worth of shares (2,215 units at $0.56), decreasing direct ownership by 5% to 39,062 units (SEC Form 4)

    4 - Avinger Inc (0001506928) (Issuer)

    1/24/25 9:34:02 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    $AVGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital reiterated coverage on Avinger with a new price target

    Aegis Capital reiterated coverage of Avinger with a rating of Buy and set a new price target of $2.00 from $2.50 previously

    11/15/21 12:33:44 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on Avinger with a new price target

    B. Riley Securities initiated coverage of Avinger with a rating of Buy and set a new price target of $2.50

    6/29/21 6:16:21 AM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    $AVGR
    Leadership Updates

    Live Leadership Updates

    View All

    Avinger Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer

    REDWOOD CITY, CA / ACCESSWIRE / August 5, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the appointment of Thomas P. Davis, MD, FACC, as Chief Medical Officer for its peripheral business. As a highly experienced interventional cardiologist and key opinion leader (KOL) in the peripheral vascular space, Dr. Davis has operated at the forefront of medical device innovation and advancing patient care in a career spanning more than three decades. Dr. Davis has pioneered the use of several cutting-edge interventional technolo

    8/5/24 8:00:00 AM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council

    SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

    9/7/22 8:30:00 AM ET
    $AFIB
    $AVGR
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    Avinger Announces Annual Meeting Results

    REDWOOD CITY, CA / ACCESSWIRE / December 23, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced results of its annual meeting of stockholders (the "Annual Meeting"), concluded on December 23, 2020. At the Annual Meeting, proposals were presented to elect one director to serve until the 2023 annual meeting, to ratify the appointment of the Company's public accountant for the year ended December 31, 2020, to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock spl

    12/23/20 4:50:00 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    $AVGR
    Financials

    Live finance-specific insights

    View All

    Avinger Reports Third Quarter 2024 Results

    Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024.Third Quarter and Recent HighlightsReported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.Implemented cost reduction program designed to streamline operating costs of the peripheral business and increase focus on coronary product development

    11/7/24 4:05:00 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Avinger to Announce Third Quarter 2024 Results on November 7, 2024

    REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1- 973-528-0011 and use passcode 442577. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.co

    10/29/24 8:00:00 AM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Avinger to Announce Second Quarter 2024 Results on August 8, 2024

    REDWOOD CITY, CA / ACCESSWIRE / July 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the second quarter 2024 after the close of trading on Thursday, August 8, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1-848-280-6550 and use passcode Avinger. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.com.A

    7/29/24 8:45:00 AM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    $AVGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avinger Inc.

    SC 13G - Avinger Inc (0001506928) (Subject)

    11/14/24 3:23:30 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avinger Inc.

    SC 13G/A - Avinger Inc (0001506928) (Subject)

    11/13/24 11:13:40 AM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Avinger Inc.

    SC 13G - Avinger Inc (0001506928) (Subject)

    6/21/24 4:45:23 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care